Recital 9, Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009…

In forcesince 6 May 2009cited 25×

The duration of the protection granted by the certificate should be such as to provide adequate effective protection. For this purpose, the holder of both a patent and a certificate should be able to enjoy an overall maximum of 15 years of exclusivity from the time the medicinal product in question first obtains authorisation to be placed on the market in the Community.

The 10 that are cited most themselves, of 25.

  • Judgment of the Court (Fourth Chamber) of 24 November 2011. Medeva BV v Comptroller General of Patents, Designs and Trade Marks.Decision

    Recital 1 and recitals 4 to 10 in the preamble to Regulation No 469/2009 are worded as follows: ‘(1) Council Regulation (EEC) No 1768/92 of 18 June 1992 concerning the creation of a supplementary protection certificate for medicinal …

    24 Nov 2011 · 62010CJ0322

  • Judgment of the Court (Fourth Chamber) of 24 November 2011. Georgetown University and Others v Comptroller General of Patents, Designs and TDecision

    Recital 1 and recitals 4 to 10 in the preamble to Regulation No 469/2009 are worded as follows: Council Regulation (EEC) No 1768/92 of 18 June 1992 concerning the creation of a supplementary protection certificate for medicinal products …

    24 Nov 2011 · 62010CJ0422

  • Judgment of the Court (Third Chamber), 12 December 2013. Actavis Group PTC EHF and Actavis UK Ltd v Sanofi.Decision

    Recitals 4, 5, 9 and 10 in the preamble to Regulation No 469/2009 read as follows: At the moment, the period that elapses between the filing of an application for a patent for a new medicinal product and authorisation to place the …

    12 Dec 2013 · 62012CJ0443

  • Judgment of the Court (Fourth Chamber), 19 July 2012. Neurim Pharmaceuticals (1991) Ltd v Comptroller-General of Patents.Decision

    Recitals 1 and 4 to 10 of the SPC Regulation read as follows: Council Regulation (EEC) No 1768/92 … has been substantially amended several times. In the interests of clarity and rationality the said Regulation should be codified. ... At …

    19 Jul 2012 · 62011CJ0130

  • Judgment of the Court (Eighth Chamber) of 12 March 2015. Actavis Group PTC EHF and Actavis UK Ltd v Boehringer Ingelheim Pharma GmbH & Co. KDecision

    Recitals 4, 5, 9 and 10 in the preamble to Regulation No 469/2009 are worded as follows: At the moment, the period that elapses between the filing of an application for a patent for a new medicinal product and authorisation to place the …

    12 Mar 2015 · 62013CJ0577

  • Order of the Court (Fourth Chamber) of 25 November 2011. University of Queensland and CSL Ltd v Comptroller General of Patents, Designs and Decision

    Recital 1 and recitals 4 to 10 in the preamble to Regulation No 469/2009 are worded as follows: ‘(1) Council Regulation (EEC) No 1768/92 of 18 June 1992 concerning the creation of a supplementary protection certificate for medicinal …

    25 Nov 2011 · 62010CO0630

  • Judgment of the Court (Grand Chamber) of 25 July 2018. Teva UK Ltd and Others v Gilead Sciences Inc.Decision

    It must be added that, in view of the interests referred to in recitals 4, 5, 9 and 10 of Directive 469/2009, it cannot be accepted that the holder of a basic patent in force may obtain an SPC each time he places on the market in a Member …

    25 Jul 2018 · 62017CJ0121

  • Order of the Court (Fourth Chamber) of 25 November 2011. Daiichi Sankyo Company v Comptroller General of Patents, Designs and Trade Marks.Decision

    Recital 1 and recitals 4 to 10 in the preamble to Regulation No 469/2009 are worded as follows: Council Regulation (EEC) No 1768/92 of 18 June 1992 concerning the creation of a supplementary protection certificate for medicinal products …

    25 Nov 2011 · 62011CO0006

  • Judgment of the Court (Fourth Chamber) of 21 March 2019. Abraxis Bioscience LLC v Comptroller General of Patents.Decision

    Recitals 3 to 5 and 7 to 10 of Regulation No 469/2009 state as follows: Medicinal products, especially those that are the result of long, costly research will not continue to be developed in the [European Union] and in Europe unless they …

    21 Mar 2019 · 62017CJ0443

  • Judgment of the Court (Third Chamber), 12 December 2013. Georgetown University v Octrooicentrum Nederland.Decision

    Recitals 4, 5, 9 and 10 in the preamble to Regulation No 469/2009 read as follows: At the moment, the period that elapses between the filing of an application for a patent for a new medicinal product and authorisation to place the …

    12 Dec 2013 · 62012CJ0484